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The introduction of stents in the treatment of
coronary artery disease has dramatically altered the
practice of coronary artery bypass grafting surgery.
New complications caused by percutaneous coronary
interventions (PCI) with the implantation of stents has
emerged and affected the result when surgery is
subsequently required.
The stent was initially utilized for the treatment of
complications associated with percutaneous coronary
angioplasty, specifically acute occlusion and
restenosis. Employed as support, an expanded metallic
mesh impedes the phenomenon of 'recoil', one of the
factors responsible for genesis of post-angioplasty
restenosis.
However, recent evidence has demonstrated that
the coronary stent may induce the appearance of
Systemic Inflammatory Response Syndrome (SIRS)
[1,2], where restenosis after stent implantation
constitutes the earliest manifestation of an inflammatory
reaction. SIRS, the consequent endothelial dysfunction
and ischemia are events that follow and are little
understood.
The inflammatory reaction triggered by the
insertion of the stent is caused and maintained by the
following factors:
1 - expansion of the stent with rupture of the
atherosclerotic plaque and the tunica media
2 - maintenance of the radial pressure of the stent
on the arterial wall
3 - the presence of a metallic foreign body
4 - ischemic phenomenon induced by endothelial
dysfunction
The implantation and expansion of the stent
determines a coronary vascular injury that is very much
more severe to the lesion produced by balloon
angioplasty. This follows the concept of "the bigger
the better", initially suggested by KUNTZ et al. [3]
where the high dilation pressure [4], in which the
expansion of the stent creates the greatest luminal
diameter possible, causes severe structural alterations
to the wall of the coronary artery. Figure 1 demonstrates
the severity of the lesion caused on the arterial wall by
the expansion of the stent with the rupture of the
atherosclerotic plaque and the tunica media.
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Fig. 1 - Transversal section of the coronary artery
demonstrating the injuries caused by stent expansion (the
stent was removed for fixing). There is rupture of the
atherosclerotic plaque (white arrow) and the tunica media
(black arrow)
Maintenance of the radial pressure of the stent to
prevent 'recoil' acts as a factor of aggression,
stimulating the inflammatory response. It has been
demonstrated that the initial inflammatory reaction is
more accentuated at the points of greatest pressure of
the metallic structure on the arterial wall, as can be
seen in figure 2.
The presence of the intra-coronary metallic mesh is
as a foreign body, causing the appearance of a
granuloma-type continuous inflammatory response.
Finally, the endothelial dysfunction consequent to the
inflammatory response induces thrombosis and
ischemic phenomenons, with the inhibition of
vasodilator factor synthesis (in particular nitric oxide)
and increases in the liberation of endothelin 1, a potent
vasoconstrictor.
There are no doubts, nowadays, that atherosclerotic
disease has an inflammatory origin. Mechanical injuries
of the arteries or exposure to atherogenic stimuli induce
an inflammatory response, with adherence and
migration of leukocytes to the vessel wall creating
macrophages (which form foam cells). There is
liberation of growth factors and cytokines with
recruitment of smooth muscle cells and stimulation of
neo-intimal proliferation, leading to the accumulation
of lipids and endothelial dysfunction [5].
The insertion of a stent acts in synergy with the
atherosclerotic plaque, increasing the inflammatory
response that already exists in the coronary arterial
wall. As a consequence, there may be acceleration in
the evolution of atherosclerotic disease. Figure 3
illustrates a typical example of accelerated progression
of coronary disease, with the development of injury of
the left coronary branch in a patient 14 months after
stent implantation.
Recent studies show that inflammatory markers
increase in the blood after stent implantation. ALMAGOR
et al. [1] demonstrated that levels of reactive protein C
in patients after coronary stent implantation were
persistently high over the medium term, constituting a
continuous systemic inflammatory response.
Another study demonstrated that there is long-term
persistence of the high levels of sanguineous
inflammatory mediators in patients submitted to stent
implantation. Serous levels of the soluble receptors of
interleukin-2 (sIL-2R) for activation of T-lymphocytes
(markers of immunity mediated by cells) are still high
four months after stent implantation. The pro-
inflammatory cytokines and the acute phase proteins
are also precociously liberated in the peripheral
circulation and immunity mediated by cells persists for
an indefinite time after stent implantation [6].
NAVARRO-LOPEZ et al. [7] demonstrated that at 6
months of evolution, patients with stent restenosis
presented with an increase in the inflammatory activity
expressed by a rise of the cytotoxic T lymphocytes
CD3+/CD56+ and activated monocytes CD11b.
These findings of persistently high inflammatory
markers confirm the existence of continuous SIRS after
the implantation of coronary stents.
Some diseases are recognized by their evolution
with a pattern of persistently high inflammatory markers.
The prognosis is still not known, but these patients
have a tendency to present with recurrent infections
and an increase in the incidence of osteo-articular
events.
Mechanical injury and subsequent inflammation of
the coronary arterial wall produce the appearance of
weak zones, causing the formation of aneurysms, as
can be seen in Figure 4. Evolution and prognosis of
these aneurysms of the coronary artery are little
studied, but published reports confirm that they can
rupture and cause a fatal outcome [8].
As an additional factor of the inflammatory reaction
to PCI with stents, there are the acute and chronic
ischemic processes. Acute ischemia is caused by two
factors in relation to stent implantation. The first is by
atheroembolism following the expansion of the stent
with rupture of the atherosclerotic plaque and liberation
of its contents, with the creation of numerous emboli
that occlude the distal coronary microcirculation. The
other mechanism involved is the obstruction of the
lateral branches of the coronary artery in the region of
the stent implantation site, with localized infarctions of
the regions supplied by these branches. Cantor et al.
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Fig. 3 - Development of left coronary artery branch injury
14 months after stent implantation in the anterior
descending artery.
Fig. 2 - Presence of significant inflammatory infiltrate
predominantly at the contact site of the mesh of the stent
(marked with an asterisk) with the coronary artery wall.
[9], studying the incidence and clinical significance of
augmented cardiac troponin I (cTnI) after PCI,
demonstrated that 48% of the patients had on increase
in cTnI levels after PCI, compatible to acute myocardial
infarction. This increase of cTnI was associated with a
significant increase in the risk of death or infarction
and worse clinical outcomes in the first 90 days after
the procedure.
Chronic ischemia occurs following deterioration of
the endothelial function, owing to persistence of the
coronary inflammatory response. It has been
demonstrated that there is an inhibition of the nitric
oxide synthesis and liberation of vasoconstrictor
factors (mainly endothelin-I) [10]. Consequently there
is loss of the vasodilation capacity of the coronary
artery and ensuing prejudice to the offer-demand linking
mechanism of oxygen for the cardiac muscle. This
results in sequential situations of myocardial ischemia
due to the impossibility of increasing the coronary
blood flow in situations of increased demand of the
cardiac muscle. Also this explains the situations that
patients with stents present with angina or myocardial
infarction with the stent apparently patent, as evidenced
by cinecoronariography.
Furthermore, there is evidence of systemic
repercussions of endothelial dysfunction. WU et al.
[11] investigated systemic endothelial function in
forearm arteries of patients after stent implantation.
In patients with angiographic restenosis of the stent,
reactive hyperemia of the forearm was seen to be
worse when compared with control individuals and
this was associated with liberation of endothelin-I,
which was elevated in the coronary circulation
immediately after PCI.
The mechanism of thrombosis might still be
aggravated by exposure to the metallic structure of the
stent in the lumen of the artery, as, frequently,
endothelial development surrounding the metallic parts
remains incomplete (Figure 5).
Clopidogrel, a platelet anti-aggregate, has been
extensively used to attempt to control the thrombotic
process. However, recent studies show that
antithrombotic protection of clopidogrel is incomplete,
exhibiting a considerable individual heterogeneity, with
some individuals demonstrating potent antiplatelet
inhibition and others a weak response [12]. Even more
recently, another complicating factor arose linked to
the utilization of clopidogrel. This drug is capable of
inducing SIRS, as was demonstrated by WOLF et al.
[13]. Is this another factor that acts in synergy with the
inflammatory reaction of atherosclerotic disease and
with an inflammatory response induced by the insertion
of the stent, increasing even more the expression of
SIRS in patients?
Finally, the introduction of technology of stents
coated with drugs (DES-drug-eluding stents) increased
another variable interacting with the arterial wall. These
drugs possess effects that lead to the appearance of
other specific complications (idiosyncrasy). Examples
are the recent launch of stents with rapamicin
(sirolimus) (Cypher TM) and paclitaxel (Taxus TM).
Despite of the antiproliferative effect of sirolimus
(rapamicin) apparently manifested and a reduction of
the endothelial growth and intra-stent restenosis, the
inflammatory response is aggravated at the ends of
the stent, producing an effect of increasing the
inflammatory response and intra-segmental restenosis
[14] (figure 6).
Sirolimus also has been associated with the
appearance of reactions of hypersensitivity to
medicines, such as pain, exanthema and cutaneous
eruptions, respiratory alterations, urticaria, pruritus,
fever and blood pressure alterations [15]. The long-
term effects of these complications are unknown,
Furthermore, sirolimus has been demonstrated as a
platelet agonist, stimulating platelet aggregation and
inducing intra-coronary thrombosis [16]. This
complication is currently being investigated by the
Food and Drug Administration in the USA [15].
Other stents coated with drugs will probably exhibit
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Fig. 5 - Incomplete endothelial development of the coronary
artery after conventional stent implantation.
Fig. 4 - Aneurysms of the coronary arteries after stent
implantation.
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Fig. 7 - Incomplete endothelial development of a saphenous
vein graft after implantation of a stent coated with rapamicin,
with exposure of the metallic mesh of the stent in the vessel
lumen.
Fig. 6 - Histological study of the distal coronary arterial wall
at the implantation site of a stent coated with rapamicin,
exhibiting intense fibrotic process, with cellular degeneration
and proliferation of the extracellular matrix, suggestive of an
accentuated inflammatory process.
specific side effects, forcing cardiac surgeons and
clinical cardiologists to employ specific interventions
for each type of device [17].
As suggested, the most obvious implication is that
probably the coronary artery bypass grafting surgery
may not provide patients with previously implanted
stents the same results as those results obtained in
patients without stents, results published over the last
decades. The consequences of chronic inflammation
of the coronary artery (arteritis) and myocardium
(myocarditis) are still unknown, as are how these
factors can affect the prognosis of the patient. Only
future research in this area might elucidate all these
questions.
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